(S) -BI 665915

(S) -BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S) -BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S) -BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production[1].

Product Specifications

CAS Number

[1360550-05-5]

UNSPSC

12352005

Target

FLAP

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s-bi-665915.html

Solubility

10 mM in DMSO

Smiles

O=C(N(C)C)CN1N=CC(C2=NC([C@@](C3CC3)(C4=CC=C(C5=CN=C(N)N=C5)C=C4)C)=NO2)=C1

Molecular Formula

C24H26N8O2

Molecular Weight

458.52

References & Citations

[1]Takahashi H, et al. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4- (3-{ (r) -1-[4- (2-amino-pyrimidin-5-yl) -phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl) -pyrazol-1-yl]-N, N-dimethyl-acetamide (BI 665915) . J Med Chem. 2015 Feb 26;58 (4) :1669-90.